Replies to post #233595 on Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

IPIX MAJOR CATALYSTS APPROACHING
I'm still up there with my figures. And if we make it, and get full market penetration, I'm up there with George's numbers too.
My opinion is, I hate it when a CEO sets a deadline. Great to have milestones but just about every company out there that sets a deadline in the bio sector just ends up screwing himself, the company and shareholders. Can it happen by the 9/30? Certainly should have topline data for prurisol, possibly even by the end of July. That's one. BTD for brilacidin - an answer within 30 days of application right? That's two. Both of those milestones SHOULD see a very notable market reaction.
Finally, getting a deal done that brings in the double digit millions we need to move forward. I'm into September on that one. But it could happen. That's three.

$30 - $60 MILLION upfront IMO just for the OM. That's being realistic. Plus milestones. Yes, Aspire set themselves up nicely. But if IPIX follows through, we benefit as well. Handsomely.

Nice work DaubersUP.

Posted by: DaubersUP
In reply to: None Date:7/5/2018 4:32:23 PM
Post #233552 of 233595


Here is something interesting. So in the PR Agreement with Aspire:

· $2 million upon announcement of the Company entering into a licensing arrangement with a pharmaceutical company for any of the Company’s clinical assets that will include an initial payment to the Company of an amount in the double-digits millions of dollars.

http://www.ipharminc.com/press-release/2018/6/28/innovation-pharmaceuticals-announces-7-million-milestone-funding-agreement-with-aspire-capital


Here is from the Purchase Agreement

Provided that on or before September 30, 2018, the Company announces the BD Agreement, and provided that the closing price of the Common Stock on such Date of Announcement was equal to or greater than $0.50, then, on or before the second Business Day after the Company announces the BD Agreement, the Company shall sell to the Buyer, and the Buyer shall purchase from the Company, the Fourth Purchase Shares and the Buyer shall pay to the Company as the purchase price therefor, via wire transfer, Two Million Dollars ($2,000,000) (the “Fourth Purchase Shares Purchase Price”). At the Buyer’s discretion, in lieu of purchasing the Fourth Purchase Shares or part thereof, the Buyer may elect to purchase Pre-Funded Warrants. The price for each Pre-Funded Warrant purchased in lieu of Fourth Purchase Shares will be the result of multiplying (x) the number of warrant shares that the Buyer may purchase under such Pre-Funded Warrant by (y) a number equal to the Fourth Purchase Price reduced by $0.01. The exercise price for each warrant share will be $0.01, and the Fourth Purchase Shares Purchase Price shall be reduced by the aggregate exercise price for the Pre-Funded Warrants purchased in lieu of Fourth Purchase Shares.


(c) “BD Agreement” means a significant licensing arrangement with a pharmaceutical company that will include an initial (“up-front”) payment to the Company in an amount in the double-digits millions of dollars and will arrange for such pharmaceutical company to undertake the continuing development of the Company’s Brilacidin compound in the indication of Oral Mucositis, including the conducting and funding of clinical trials aiming towards the filing of an NDA.
https://www.bamsec.com/filing/147793218003269/4?cik=1355250






So to me ----- I think B-OM will be our first license deal!!! At first based on the PR and 8-K it makes it sound like any of the company's assets with a double digit million upfront could be in the works, but when you hammer it out into the details of the "BD" (Business Development) details it clearly states OM.

Interesting.

https://www.ipharminc.com/press-release/2018/6/29/innovation-pharmaceuticals-announces-database-lock-for-phase-2b-trial-of-oral-prurisol-for-psoriasis

https://www.ipharminc.com/press-release/2018/6/28/innovation-pharmaceuticals-announces-7-million-milestone-funding-agreement-with-aspire-capital

https://www.sec.gov/Archives/edgar/data/1355250/000147793218003269/0001477932-18-003269-index.htm

https://www.sec.gov/Archives/edgar/data/1355250/000147793218003252/ipix_424b5.htm

Quote:
Sox's dd post sums things up pretty well imo...

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140577387

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140549037

https://www.ipharminc.com/overview/

Ready to rock and roll.
$IPIX

all imho.

[slcimmuno]

Huh? A vast majority of deals, esp for late stage drugs, have the trial costs *covered* by the Licensee — who is buying the right to drug to advance to market and reap the bulk of the rewards $$$

I’m almost certain this would be the situation re any IPIX Deal — so add another $10-20m (likely cost of a Ph 3) to the upfront $10+ million... will also be interesting to see milestones, royalty splits

Some more context
https://www.slideshare.net/gowlings/hot-topic-life-sciences-licensing-trends-and-issues

If deal is for OM — per Daubers find (nice sleuthing) — and is successfully executed, then IPIX has already outperformed by 10x (per the Aspire agreement/signaling... “double digits millions”) what Onxeo got from Monopar in upfront - only $1mil

Would be a job well done by IPIX

https://www.onxeo.com/onxeo-grants-exclusive-worldwide-license-validive-developed-treatment-oral-severe-mucositis-monopar-therapeutics/

Also see Monopar “will drive and fund all remaining development and regulatory activities” (again this is standard operating procedure)

Always good to check ones homework

[CallMeCrazy]

What utter nonsense.

This is actually very bad news. In order to get the additional money from aspire, ipix not only has to receive 10mm dollars, they also must convince the pharma to pay for the trial. This is not a promising development. Aspire is really doing a brilliant CYA.

These are minimal requirements that I'm sure Leo knows the successful CDA holder is prepared to meet. Leo agreed to this because in his negotiations with CDA holders he has determined that this will not be a problem.

I'm highly confident that Leo (The Mailman) Ehrlich will deliver.

[TheDane]

Your conclusions are bullshit. Totally illogical. Go IPIX!

[seek the light]

SS...I disagree....This is nonsense. Agenda based to try to fool the inexperienced investors.

A better statement would be why was Milestone #3 included as a precondition of getting another $2 million from Aspire? When the terms, if met would insure IPIX of having enough funds from the partner to not even need this option!

Here is my reasoning about milestone #3, if IPIX announces a double digit upfront payment [imo $30 million range] plus the partner agrees to fund and run any further clinical trials to carry B all the way to FDA approval for OM, IPIX can do a broker sponsored secondary to raise ALL THE MONEY they need at prices much higher [$5/share or higher]. So if #3 is achieved they do not need a mere $2 million more from Aspire. And what if the partnership for B includes more than OM? #3 looks like a favor to Aspire to me!!


Furthermore i think if option #1 is achieved, then option #3 is a given and helps determines the amount of the upfront payment and probably the ongoing royalty payment on sales after approval. In other words, both would be larger amounts if #1 is achieved.